Effect on Metabolic Parameters of Abilify in SPR

Seoul National Hospital

Status: Unknown

Conditions: Schizophrenia; Metabolic Syndrome

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT00569764

snh002

MSABLI

Details and patient eligibility

About

To measure the long-term changes in weight and plasma lipids after switching antipsychotic treatment to aripiprazole

Full description

To measure the long-term changes in weight, plasma lipids and fasting blood glucose after switching antipsychotic treatment to aripiprazole, 1 year, open label studies in out and in-patients with schizophrenia.

The measurement of weight and lipid profile and fasting blood glucose will be measured at baseline and every 3 months for 1 year.

Enrollment: 100 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• DSM-IV diagnosis with schizophrenia
• who signed an informed consent

Exclusion criteria

• comorbid with substance abuse or substance dependence
• pregnancy or lactation

Trial design

100 participants in 1 patient group

observational

Description:

patients with schizophrenia who want to change an antipsychotics due to metabolic side effect